NNC0491 6075
Alternative Names: NN C04916075Latest Information Update: 15 Sep 2023
At a glance
- Originator Novo Nordisk
- Class Antihyperlipidaemics
- Mechanism of Action ANGPTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 07 Aug 2023 Phase-I clinical trials in Dyslipidaemias in USA (IV) (NCT05979428)
- 07 Aug 2023 Phase-I clinical trials in Dyslipidaemias in USA (SC) (NCT05979428)